A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.
Forschungsgruppe Quanteneffekte bei Krankheiten (qrdrg.xonl.de)
Copyright © 2024 MEDIZIN.NEWZS.de - Quantum Related Diseases Research Group (QRDRG)